LINC00330 and esophageal squamous cell carcinoma: LINC00330 inhibited ESCC progression by disrupting the CCL2/CCR2 axis and its downstream signaling pathways in an autocrine fashion and by impeding CCL2-mediated TAM reprogramming in a paracrine manner.